Who we are.

Our leadership team has extensive experience in developing RNA therapeutics and building successful biopharmaceutical companies.

Bo Rode Hansen, MBA, PhD

President and Chief Executive Officer

Bo Rode Hansen, MBA, PhD joined Genevant in October 2018, taking on the roles of President and Chief Executive Officer in November 2018.  Previously, Bo served as Global Head of RNA Therapeutics at Roche pRED and General Manager of the Roche Innovation Center Copenhagen. Prior to Roche, he was Executive, Vice President and Head of Drug Discovery & Alliance Management at Santaris Pharma (acquired by Roche). Over the course of his career, Bo has led wholly owned subsidiaries, innovation and numerous partnerships with GSK, Wyeth, Pfizer, Bristol Myers Squibb, Shire and Roche. He has led over 50 RNA therapeutic discovery programs resulting in 10 clinical candidates. He holds a PhD from Copenhagen University, and an executive MBA from Henley Business School (UK).

Elizabeth A. Czerepak

Chief Financial Officer and Chief Business Officer

Elizabeth Czerepak has served as Chief Financial Officer and Chief Business Officer of Genevant since May 2018.  Most recently, Elizabeth was Chief Financial Officer and Executive Vice President, Corporate Development of Altimmune, Inc.  Previously, she held executive positions in finance, business development and corporate development at a number of public and private biotech and pharma companies, including BASF (Knoll) Pharma, Hoffmann-La Roche and Merck & Co., as well as working as Managing Director and General Partner of the BSHI venture fund at JPMorgan and Bear Stearns, where she led 13 biotech investments.  Elizabeth served a primary role in Roche’s $5.4bn acquisition of Syntex and BASF Pharma’s $6.9bn sale to Abbott.  She holds an MBA from Rutgers University and a B.A. from Marshall University.

Margrit Schwarz, MBA, PhD

Chief Scientific Officer and Head of R&D

Margrit Schwarz, MBA, PhD has acted as Chief Scientific Officer and Head of Research and Development for Genevant since January 2019. She is currently the Managing Director of Blackway Bioscience.  Previously, Margrit served as Vice President and Global Head, External Innovation, Therapeutic Modalities of Roche, Vice President and Therapeutic Area Head at Boehringer Ingelheim, and Director, Research at Amgen, as well as in scientific leadership roles at Roche and Tularik (acquired by Amgen).  She has successfully built preclinical pipelines for cardiometabolic diseases and dyslipidemia, with five drug candidates advanced into clinical development under her tenure (including an anti-PCSK9 molecular antibody launched in 2015 as Repatha® for the treatment of hypercholesterolemia). Margrit holds a PhD in Biochemistry from the University of Cologne, Germany and an MBA from Columbia University and is the author of numerous publications and several issued patents.

Pete Zorn, JD

Chief Operating Officer

Pete Zorn, Esq. has served as Chief Operating Officer of Genevant since January 2019.  Previously, Pete was Chief Corporate Officer and General Counsel of Albireo Pharma where he led the corporate development, legal, corporate communications and human resource functions, General Counsel and Vice President, Communications of Santaris Pharma (acquired by Roche) and Senior Vice President and General Counsel of Targacept. He has a JD from the University of North Carolina at Chapel Hill and an AB from Harvard University.

Peter Lutwyche, PhD

Chief Technology Officer & Vancouver Site Head

Pete Lutwyche has served as Chief Technology Officer of Genevant since its inception in April 2018.  Previously, Pete was Chief Technology Officer of Arbutus Biopharma, where he led the development of the company’s nucleic acid-delivery technology, and Head of Pharmaceutical Development at QLT, where he contributed to the development and commercialization of VISUDYNE®. He has over 20 years of experience in the field of nucleic acid-based products.  Pete holds a PhD in Chemistry from the University of British Columbia and a BS in Chemistry from the University of Warwick.

James Heyes, PhD

SVP, Technology Development

James Heyes has served as Senior Vice President, Technology Development of Genevant since its inception in April 2018.  Previously, James was Vice President, Drug Delivery of Arbutus Biopharma.  He brings over 17 years of experience in lipid chemistry and nucleic acid drug delivery and is an inventor of next generation lipid nanoparticle and ligand conjugate technology, with more than 20 issued and published U.S. patents in the area. James designed the lipid components enabling the first demonstration of RNA interference in primates and subsequently the advancement of 13 clinical candidates.  He holds a PhD in Medicinal and Pharmaceutical Chemistry from the University of London and a BS in Chemistry from the University of Manchester.

Janielle Newland

Vice President, People & Culture

Janielle brings over 20 years of experience focused on global people topics within the health, bioscience, and the financial services industries. Throughout her career, Janielle led and coached companies through rapid organic and inorganic growth, while helping them build or strengthen their capabilities to attract, motivate, and retain talent that delivers on business outcomes. Along with her consulting practice supporting biotech startups, Janielle has also worked for Thermo Fisher Scientific, the U.S. affiliates of Merck KGaA Darmstadt, EMD Serono and MilliporeSigma, and Covidien/Medtronic.

Paris Panayiotopoulos

Executive Chairman

Paris most recently served as President and CEO of ARIAD Pharmaceuticals through its acquisition by Takeda in 2017. Prior to ARIAD, Paris was President of EMD Serono, the North American biopharmaceutical business of Merck KGaA, as well as President of Merck Serono in Japan and the Serono Research & Development Institute. He has led partnerships with Pfizer, Bristol Myers Squibb, Eli Lilly & Co., Dainippon Sumitomo Pharma, Mitsubishi Tanabe, Otsuka, Incyte, and others.